PT  - JOURNAL ARTICLE
AU  - Bolton, Marcus J.
AU  - Ort, Jordan T.
AU  - McBride, Ryan
AU  - Swanson, Nicholas J.
AU  - Wilson, Jo
AU  - Awofolaju, Moses
AU  - Greenplate, Allison R.
AU  - Drapeau, Elizabeth M.
AU  - Pekosz, Andrew
AU  - Paulson, James C.
AU  - Hensley, Scott E.
TI  - Antigenic and virological properties of an H3N2 variant that will likely dominate the 2021-2022 Northern Hemisphere influenza season
AID  - 10.1101/2021.12.15.21267857
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.15.21267857
4099  - http://medrxiv.org/content/early/2021/12/16/2021.12.15.21267857.short
4100  - http://medrxiv.org/content/early/2021/12/16/2021.12.15.21267857.full
AB  - Influenza viruses have circulated at very low levels during the COVID-19 pandemic, and population immunity against these viruses is low. Influenza virus cases have been increasing in the Northern Hemisphere involving an H3N2 strain (3C.2a1b.2a2) with a hemagglutinin (HA) that has several substitutions relative to the 2021-2022 H3N2 vaccine strain. Here, we show that one of these substitutions eliminates a key glycosylation site on HA and alters sialic acid binding. Using glycan array profiling, we show that the 3C.2a1b.2a2 H3 maintains binding to an extended bi-antennary sialoside and replicates to high titers in human airway cells. We found that antibodies elicited by the 2021-2022 Northern Hemisphere influenza vaccine poorly neutralize the new H3N2 strain. Together, these data indicate that 3C.2a1b.2a2 H3N2 viruses efficiently replicate in human cells and could potentially cause an antigenic mismatch if they continue to circulate at high levels during the 2021-2022 influenza season.Competing Interest StatementSEH reports receiving consulting fees from Sanofi Pasteur, Lumen, Novavax, and Merck.Funding StatementThis project has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00015, Contract No. 7N593021C00045, and Grant Nos. 1R01AI108686 and 1R01AI114730. SEH holds an Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of the University of Pennsylvania.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.